Credent Connect N Care Limited (CREDENT)
சுருக்கம்
பங்குச் சந்தை செயல்பாடு12 நவ. 2026
- டெலிவரி
- 73.2% எதிர் சராசரி 79.86%
- வால்யூம் அதன் சராசரியுடன் ஒப்பீடு
- 0.6×
நிகழ்வுகள்
- சமீபத்திய முடிவுகள்
- H1 FY27, filed 28 Oct 2026
- இயக்குநர் குழுக் கூட்ட அறிவிப்பு
- 28 அக். 2026
பங்குச் சந்தைத் தரவு. ஒவ்வொரு எண்ணும் அதன் சொந்தப் பக்கம் காட்டும் வடிவத்திலேயே; தேதிகள் தரவின் தேதிகள். தகவலுக்கு மட்டுமே, முதலீட்டு ஆலோசனை அல்ல.
📈 பங்கு விலை & நிகழ்வுகள்
H1 FY27 முடிவுகள்
Credent Connect N Care Limited reported H1 FY27 results on 28 Oct 2026: revenue ₹138 Cr, and net profit ₹14.7 Cr; the operating margin was 13.2%.
| H1 FY27 (₹ கோடி) | மதிப்பு | YoY | முந்தைய அரையாண்டுடன் ஒப்பீடு |
|---|---|---|---|
| வருவாய் | ₹138 | — | — |
| செயல்பாட்டு லாபம் | ₹18.2 | — | — |
| நிகர லாபம் | ₹14.7 | — | — |
| EPS (₹) | 10.18 | — | — |
| செயல்பாட்டு லாப வரம்பு | 13.2% | — | — |
லாபத்தின் தரம்: வரிக்கு முந்தைய ₹15.0 கோடி லாபத்தில், ₹14.9 கோடி (100%) முக்கிய வணிகத்திலிருந்து வந்தது; மீதம் பிற வருமானம் மற்றும் ஒருமுறை வரவுகளிலிருந்து வந்தது.
CREDENT டெலிவரி சதவீதம்
க்கான NSE EOD தரவு
On Thu, 12 Nov 2026, 73.2% of the CREDENT shares traded on NSE were taken to delivery, against the stock's own 20-session average of 79.86%. That is close to its usual level.
கடந்த 5 அமர்வுகளில் டெலிவரி: 85.0% · 79.7% · 70.4% · 74.6% · 73.2%
பங்குச் சந்தை வெளியிட்டவற்றின் விளக்கம், பரிந்துரை அல்ல. "accumulation" அல்லது "லாங் பில்டப்" போன்ற பெயர்கள் எண்களில் உள்ள ஒரு வடிவத்தை குறிக்கின்றன. டெலிவரி எவ்வாறு பகுப்பாய்வு செய்யப்படுகிறது
📢 சமீபத்திய கார்ப்பரேட் அறிவிப்புகள்
Credent Connect N Care Limited has submitted an intimation to the stock exchange regarding a schedule of upcoming analyst/institutional investor meetings. The brief document was signed digitally on November 8, 2026. Detailed schedules, participating institutions, and presentation materials were not provided in the document extract. Such interactions are routine procedural compliance disclosures under SEBI listing regulations.
- Intimation filed regarding schedule of analyst or institutional investor meetings
- Filing digitally signed by Tarun Sharma on 2026-11-08 at 01:24:47 IST
- Specific meeting dates, agendas, and participant details not disclosed in the extract
Credent Connect N Care Limited has entered into an agreement to grant an unsecured inter-corporate loan of ₹4.50 crore to Kartavya Healtheon Private Limited. The loan carries nil interest up to November 25, 2026, after which unsettled amounts will incur interest at 12% per annum compounded monthly. As part of the terms, Credent holds an election right to acquire up to 26% equity share capital in the borrower on a fully diluted basis. The borrower is required to utilize the loan entirely toward repaying its outstanding OCPS and other loans.
- Unsecured inter-corporate loan of ₹4.50 crore granted to Kartavya Healtheon Private Limited
- Nil interest until November 25, 2026, and 12% per annum compounded monthly thereafter
- Option for lender to acquire up to 26% equity share capital on a fully diluted basis
- Borrower must utilize funds solely to repay its OCPS and other existing loans
- Parties are not related to the promoter/promoter group and the transaction is not a related-party deal
Credent Connect N Care Limited has submitted the transcript for its H1 FY27 earnings conference call held on October 29, 2026. The company highlighted its transition to an integrated healthcare logistics and pre-analytics platform, noting historical revenue growth from INR 25 crore in 2022 to INR 75 crore in 2024. Its operational footprint currently covers approximately 19,000 pin codes with over 2,200 phlebotomists and associations with 2,500+ laboratories. Management confirmed plans to defer Middle East overseas expansion until at least next year due to regional geopolitical conflicts.
- Turnover crossed INR 25 crore in 2022, INR 50 crore in 2023, and INR 75 crore in 2024
- Pan-India network spans approximately 19,000 pin codes and associations with more than 2,500 laboratories
- Field force includes 2,200+ trained phlebotomists supported by 5+ courier partners and 35+ air routes
- International expansion to the Middle East delayed until at least H1 next year due to geopolitical instability
Credent Connect N Care Limited has released its H1FY27 investor presentation following its recent NSE SME listing. Consolidated revenue from operations grew 53% YoY to ₹1,381 Mn, while EBITDA grew 53% YoY to ₹182 Mn with a 13% margin. Profit after tax rose 95% YoY to ₹147 Mn, aided by a one-time tax credit of ₹17.8 Mn. The company outlined a target of ~45% revenue CAGR through FY30 across its healthcare logistics and phlebotomy services.
- Revenue from operations grew 53% YoY to ₹1,381 Mn in H1FY27 compared to ₹900 Mn in H1FY26
- EBITDA increased 53% YoY to ₹182 Mn with an EBITDA margin of 13%
- PAT surged 95% YoY to ₹147 Mn (inclusive of a one-time tax credit of ₹17.8 Mn)
- Operating cash flow stood negative at -₹39 Mn for Sept-26 period, while cash and bank balances reached ₹742 Mn following IPO financing
- Company is targeting ~45% revenue CAGR through FY30
In its first half-yearly results since listing, Credent Connect N Care reported consolidated revenue of ₹138.09 crore for H1 FY27, up 53.4% YoY. EBITDA grew 53.4% YoY to ₹18.19 crore with steady margins of 13.17%, while PAT increased 94.7% YoY to ₹14.65 crore (adjusted PAT up 71.0% to ₹12.87 crore excluding a one-time tax credit). The company provided full-year FY27 guidance of over ₹320 crore in revenue and ₹28 crore in PAT, implying an expected H2 FY27 revenue of approximately ₹181.91 crore.
- H1 FY27 consolidated revenue grew 53.4% YoY to ₹138.09 crore, reaching ~64% of FY26 full-year revenue
- Consolidated PAT surged 94.7% YoY to ₹14.65 crore; adjusted PAT rose 71.0% YoY to ₹12.87 crore
- EBITDA rose 53.4% YoY to ₹18.19 crore, holding EBITDA margin steady at 13.17%
- Management provided full-year FY27 guidance of revenue >₹320 crore (49.4%+ YoY) and PAT of ₹28 crore
- Strengthened post-IPO balance sheet with net worth of ₹141.99 crore and cash/bank balances of ₹74.20 crore against borrowings of ₹21.62 crore
Credent Connect N Care reported consolidated revenue of ₹138.09 crore for the half-year ended September 30, 2026, up 53.4% YoY from ₹90.03 crore in the year-ago period. Consolidated net profit for the half-year jumped 94.7% YoY to ₹14.65 crore compared to ₹7.53 crore. Alongside financial results, the board approved the elevation of Whole-Time Director Karan Sharma as Chief Executive Officer and appointed M/s RKKV & Associates as internal auditors for FY27. Cash flow from operating activities was negative at ₹(3.92) crore, primarily driven by a working capital lock-in of ₹20.02 crore in trade receivables.
- H1 FY27 consolidated revenue from operations reached ₹13,808.65 lakhs, up 53.4% from ₹9,002.96 lakhs in H1 FY26
- Net profit after tax grew 94.7% YoY to ₹1,465.06 lakhs against ₹752.51 lakhs in H1 FY26
- Karan Sharma appointed as CEO effective October 28, 2026; he holds 22,47,825 equity shares
- Company raised net proceeds of ₹8,355.67 lakhs via share capital issue during the period
- Operating cash flow was negative at ₹(392.43) lakhs due to working capital expansion, with trade receivables increasing by ₹2,002.09 lakhs
Credent Connect N Care Limited has submitted the Scrutinizer's report and voting results for its 11th Annual General Meeting held on September 29, 2026. A total of 12,913,500 votes were polled across all three agenda items, receiving 100% unanimous approval with zero dissent. The passed resolutions include adoption of FY2026 audited financial statements, re-appointment of Director Ms. Dimple Sharma, and the appointment of M/s. R K Jagetiya & Co. as Statutory Auditors. Total shareholders as on the record date of September 04, 2026, stood at 1,176.
- All 3 ordinary resolutions approved with 100% votes in favour (12,913,500 votes polled, 0 votes against)
- Adopted FY2026 audited standalone and consolidated financial statements
- Appointed M/s. R K Jagetiya & Co. (FRN: 146264W) as Statutory Auditor of the company
- Total shareholder count as on the cut-off date of September 04, 2026, was 1,176
Credent Connect N Care Limited has announced a change in Key Managerial Personnel effective September 18, 2026. Mr. Karan Sharma has resigned from the position of Chief Financial Officer citing personal reasons, with his resignation letter dated September 17, 2026. The Board has appointed Mr. Sachin Sharma, a Chartered Accountant with over 14 years of post-qualification experience across finance and M&A, as the new CFO. The Board meeting approving these changes took place on September 18, 2026, between 05:00 PM and 05:30 PM.
- CFO Karan Sharma resigned effective September 18, 2026, citing personal reasons (letter dated September 17, 2026)
- Sachin Sharma appointed as CFO and KMP effective September 18, 2026
- Incoming CFO Sachin Sharma brings 14+ years of post-qualification experience in strategic finance, M&A, and IPO readiness
- Board meeting commenced at 05:00 PM and concluded at 05:30 PM on September 18, 2026
Credent Connect N Care Limited has announced remote e-voting facilities for its upcoming 11th Annual General Meeting (AGM) through CDSL. The remote e-voting window commences on Saturday, September 26, 2026 at 9:00 AM IST and concludes on Monday, September 28, 2026 at 5:00 PM IST. The cut-off date to determine shareholder voting eligibility is Friday, September 04, 2026.
- Remote e-voting begins on Saturday, September 26, 2026 at 9:00 AM IST
- Remote e-voting concludes on Monday, September 28, 2026 at 5:00 PM IST
- Cut-off date for voting eligibility set as Friday, September 04, 2026
- Remote e-voting platform provided via CDSL for the 11th AGM
Credent Connect N Care Limited has published its Annual Report for FY2025-26 and scheduled its Annual General Meeting for September 29, 2026. For FY2025-26, the company reported consolidated revenue from operations of ₹21,416.18 lakhs, driven by Healthcare Services (43.04%), Logistics Services (25.26%), and Operations & Supply Chain Management (24.93%). As of June 30, 2026, the company operated a fleet of 97 commercial vehicles with 2,589 riders and maintained relationships with 2,530 diagnostic laboratories as of March 31, 2026.
- FY2025-26 consolidated revenue from operations stood at ₹21,416.18 lakhs
- Revenue mix led by Healthcare Services at 43.04%, Logistics at 25.26%, and Supply Chain Management at 24.93%
- Maintained relationships with 2,530 diagnostic laboratory partners nationwide as of March 31, 2026
- Fleet size stood at 97 commercial vehicles and a workforce of 2,589 riders as of June 30, 2026
- Annual General Meeting scheduled to be held on September 29, 2026
Credent Connect N Care Limited approved the Directors' Report, Annual Report, and notice convening its 11th Annual General Meeting for FY 2025-26. The Board also recommended the appointment of M/s. R K Jagetiya & Co., Chartered Accountants (FRN: 146264W), as Statutory Auditors for a 5-year term from the 11th AGM to the 16th AGM. The auditor had earlier been appointed to fill a casual vacancy caused by the resignation of the previous auditor, and the full term is now subject to shareholder approval at the upcoming AGM.
- Approved notice convening the 11th Annual General Meeting for FY 2025-26 via Video Conferencing
- Recommended appointment of M/s. R K Jagetiya & Co. (FRN: 146264W) as Statutory Auditors
- Auditor tenure proposed for 5 consecutive years from the conclusion of the 11th AGM to the 16th AGM
- Board meeting held on September 5, 2026, commencing at 05:30 PM and concluding at 06:15 PM
Credent Connect N Care Limited submitted its comprehensive investor presentation outlining its business model, FY26 financial performance, and Vision 2030 roadmap. The company reported FY26 consolidated revenue from operations of ₹214.16 Cr, with EBITDA of ₹28.46 Cr (13.29% margin) and PAT of ₹18.45 Cr (8.61% margin). Net worth stood at ₹43.79 Cr with an ROE of 61.81% and ROCE of 40.00%. Management outlined an aspiration of ~45% revenue CAGR through FY30, expanding into clinical trials, pharma, and cold-chain diagnostics.
- FY26 consolidated revenue reached ₹214.16 Cr with EBITDA of ₹28.46 Cr (13.29%) and PAT of ₹18.45 Cr (8.61%)
- Return ratios remained robust with ROE reported at 61.81% and ROCE at 40.00%
- Healthcare services (43.04%), logistics (25.26%), and operations/supply chain management (24.93%) formed the bulk of FY26 revenue
- Network spans 2,500+ associated laboratories, 6,000+ field force, and ~280 domestic corporate customers
- Vision 2030 targets ~45% revenue CAGR with sector focus spanning vaccines, IVD, cord blood, and clinical trials
நிறுவனச் சுயவிவரம்
நிதிச் செயல்திறன்
இந்த நிறுவனத்துக்கான நிதிப் பகுப்பாய்வுத் தரவு இன்னும் கிடைக்கவில்லை.
செயல்பாட்டு உந்துசக்திகள்
இந்த நிறுவனத்திற்கான செயல்பாட்டுப் பகுப்பாய்வுத் தரவு இன்னும் கிடைக்கவில்லை.
வியூக வளர்ச்சி
இந்த நிறுவனத்துக்கான வியூக வளர்ச்சிப் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
வெளிப்புறக் காரணிகள்
இந்த நிறுவனத்துக்கு வெளிப்புறக் காரணிகளின் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
ஒழுங்குமுறை & நிர்வாகம்
இந்த நிறுவனத்திற்கான ஒழுங்குமுறைப் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
அபாயப் பகுப்பாய்வு
இந்நிறுவனத்துக்கான அபாய பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
